论文信息 - Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020 - 字舞流文

Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020

J. Krell | M. Lythgoe | V. Prasad | P. Savage

[1] M. Mims,et al. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs , 2020, Annals of Internal Medicine.

[2] P. Kantoff,et al. Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[3] T. Tammela,et al. Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.

[4] B. Breyer,et al. Minority Recruitment Trends in Phase III Prostate Cancer Clinical Trials (2003 to 2014): Progress and Critical Areas for Improvement , 2019, The Journal of urology.

[5] D. Spratt,et al. Disparities in castration-resistant prostate cancer trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6] L Zhang,et al. Racial/ethnic differences in drug disposition and response: Review of recently approved drugs , 2015, Clinical pharmacology and therapeutics.